TLX 0.57% $22.99 telix pharmaceuticals limited

Ann: Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade, page-53

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 225 Posts.
    lightbulb Created with Sketch. 93

    Countdown Clock Clicks Closer to " End of July "

    Extract from this Release:


    Telix is progressing multiple marketing authorisation applications across its precision medicine (diagnostic) portfolio, including:

    • New Drug Application (NDA) submission for new prostate cancer imaging agent TLX007-CDx (PSMA-PET imaging5 ):

    Telix submitted a NDA to the FDA for a new PSMA targeting prostate cancer imaging agent designed to expand the availability, distribution and
    scheduling flexibility for PSMA-PET imaging6

    . The FDA is expected to confirm by the end of July 2024 whether the submission is accepted for review.

    Confirmation of the PDUFA7 goal date (review timeframe) is expected in early August 2024, in line with FDA procedure.
 
watchlist Created with Sketch. Add TLX (ASX) to my watchlist
(20min delay)
Last
$22.99
Change
0.130(0.57%)
Mkt cap ! $7.694B
Open High Low Value Volume
$22.97 $23.46 $22.89 $22.02M 952.9K

Buyers (Bids)

No. Vol. Price($)
3 3712 $22.95
 

Sellers (Offers)

Price($) Vol. No.
$23.06 540 2
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
TLX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.